Summary

The biopharmaceutical industry has traditionally based its livelihood on blockbuster drugs that target large, chronic disease markets, but recent setbacks have raised questions about the sustainability of this model. At the same time, specialty pharmaceutical companies have carved out profitable niches by targeting smaller indications with lower potential revenue, and consequently they have avoided competing head-on with large pharmaceutical companies.